Fluproquinolone utilization, in the emergency departments of academic medical centers - Prevalence of, and risk factors for, inappropriate use

被引:72
作者
Lautenbach, E
Larosa, LA
Kasbekar, N
Peng, HP
Maniglia, RJ
Fishman, NO
机构
[1] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[2] Univ Penn, Ctr Educ Res Therapeut, Sch Med, Philadelphia, PA 19104 USA
[3] Ortho McNeil Pharmaceut, Raritan, NJ USA
关键词
D O I
10.1001/archinte.163.5.601
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Resistance. to fluoroquinolone (FQ) antibiotics has risen markedly in recent years and has been associated with increasing FQ use; however, few data exist regarding FQ use patterns. Designing strategies to limit FQ resistance by optimizing FQ use depends on. identifying patterns of inappropriate FQ use. Use of FQs in emergency departments (EDs) has not been studied. Methods: We studied 100 consecutive ED patients who received an FQ and were subsequently discharged. Appropriateness of the indication for use was judged according to existing institutional guidelines. A case-control study was conducted to identify the prevalence of, and risk factors for, inappropriate FQ use. Results: Of 100 total patients, 81 received an FQ for an inappropriate indication. Of these cases, 43 (53%) were judged inappropriate because another agent was considered first line, 27 (33%) because there was no evidence of infection based on the documented evaluation, and 11 (14%) because of inability to assess the need for antimicrobial therapy. Although the prevalence of inappropriate use was similar across various clinical scenarios, there was a borderline significant association between the hospital in which the ED was located and inappropriate FQ use.. Of the 19 patients who received an FQ for an appropriate indication, only I received both the correct dose and duration of therapy. Conclusions: Inappropriate FQ use in EDs is extremely common. Efforts to limit emergence of FQ resistance must address the high level of inappropriate FQ use in EDs. Future studies should evaluate the impact of interventions designed to reduce inappropriate FQ use in this setting.
引用
收藏
页码:601 / 605
页数:5
相关论文
共 26 条
[1]   TOLERABILITY OF FLUOROQUINOLONE ANTIBIOTICS - PAST, PRESENT AND FUTURE [J].
BALL, P ;
TILLOTSON, G .
DRUG SAFETY, 1995, 13 (06) :343-358
[2]   Levofloxacin use at an academic teaching institution [J].
Belliveau, PP ;
Brennan, WP ;
Rothman, AL .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (19) :1791-1793
[3]   RAPID DEVELOPMENT OF CIPROFLOXACIN RESISTANCE IN METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
BLUMBERG, HM ;
RIMLAND, D ;
CARROLL, DJ ;
TERRY, P ;
WACHSMUTH, IK .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1279-1285
[4]  
*CDCP, 2001, INT TASKF ANT RES PU
[5]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[6]   Pathways for inappropriate dispensing of antibiotics for rhinosinusitis: A randomized trial [J].
Contopoulos-Ioannidis, DG ;
Koliofoti, ID ;
Koutroumpa, IC ;
Giannakakis, IA ;
Ioannidis, JPA .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (01) :76-82
[7]   Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae [J].
Diekema, DJ ;
Brueggemann, AB ;
Doern, GV .
EMERGING INFECTIOUS DISEASES, 2000, 6 (05) :552-556
[8]  
DYDEK GJ, 1992, HOSP FORMUL, V27, P185
[9]   Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones [J].
Ena, J ;
López-Perezagua, MD ;
Martínez-Peinado, C ;
Cia-Barrio, AD ;
Ruíz-López, I .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 30 (02) :103-107
[10]   Quinolone and macrolide resistance in Campylobacter jejuni and C-coli:: Resistance mechanisms and trends in human isolates [J].
Engberg, J ;
Aarestrup, FM ;
Taylor, DE ;
Gerner-Smidt, P ;
Nachamkin, I .
EMERGING INFECTIOUS DISEASES, 2001, 7 (01) :24-34